Efficacy and tolerability of histamine-2 receptor antagonist adjunction of antipsychotic treatment in schizophrenia: A meta-analysis of randomized placebo-controlled trials

Pharmacopsychiatry

Volumn 48, Issue 1, 2015, Pages 30-36

  Kishi, T ^a   Iwata, N ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

histamine 2 receptor antagonists; leptin; meta analysis; psychopathology; schizophrenia; systematic review; weight gain

Indexed keywords

CIMETIDINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LEPTIN; METIAMIDE; NEUROLEPTIC AGENT; NIZATIDINE; OLANZAPINE; PERPHENAZINE; PLACEBO; RANITIDINE; ROXATIDINE; ANTIHISTAMINIC AGENT;

ANXIETY; ARTICLE; BODY MASS; BODY WEIGHT; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INCREASED APPETITE; META ANALYSIS; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SIDE EFFECT; SIMPSON-ANGUS SCALE; SOMNOLENCE; SYSTEMATIC REVIEW; WEIGHT GAIN; XEROSTOMIA; DRUG EFFECTS; FEMALE; MALE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BODY WEIGHT; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84928567835     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0034-1390478     Document Type: Article

References (25)

1. De Hert M., Vancampfort D., Correll C. U. et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry: 2011; 199 99 105
2. Leucht S., Cipriani A., Spineli L. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet: 2013; 382 951 962
3. Correll C. U., Manu P., Olshanskiy V. et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA: 2009; 302 1765 1773
4. Kishi T., Matsuda Y., Nakamura H. et al. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatric Res: 2013; 47 149 154
5. Jacobson B. C. Body mass index and the efficacy of acid-mediating agents for GERD. Dig Dis Sci: 2008; 53 2313 2317
6. Deng C., Weston-Green K., Huang X. F. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuropsychopharmacol Biol Psychiatry: 2010; 34 1 4
7. Lett T. A., Wallace T. J., Chowdhury N. I. et al. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry: 2012; 17 242 266
8. Stip E., Lungu O., Anselmo K. et al. Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment. Transl Psychiatry 2012; 2: e128 doi: 10.1038/tp.2012.53
9. Farzin D., Hosseini S., Shafaat A. A randomized double blind clinical trial in famotidine adjuvant therapy in schizophrenia. Iran J Med Sci: 2005; 30 59 62
10. Meskanen K., Ekelund H., Laitinen J. et al. A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia. J Clins Pychopharmacol: 2013; 33 472 478
11. Poyurovsky M., Tal V., Maayan R. et al. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol: 2004; 14 332 336
12. Assuncao S. S., Ruschel S. I., Rosa Lde C. et al. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. Rev brasil psiquiatria: 2006; 28 270 276
13. Atmaca M., Kuloglu M., Tezcan E. et al. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Hum Psychopharmacol: 2003; 18 457 461
14. Atmaca M., Kuloglu M., Tezcan E. et al. Nizatidine for the treatment of patients with quetiapine-induced weight gain. Hum Psychopharmacol: 2004; 19 37 40
15. Cavazzoni P., Tanaka Y., Roychowdhury S. M. et al. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol: 2003; 13 81 85
16. Ranjbar F., Ghanepour A., Sadeghi-Bazargani H. et al. The effect of ranitidine on olanzapine-induced weight gain. BioMed Res Int: 2013; 2013 639391
17. Kay S. R., Opler L. A., Lindenmayer J. P. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Supplement: 1989; DOI: 59-67
18. Guy W., Bonato R. R. Manual for the ECDEU Assessment Battery. 2nd ed. Chevy Chase, Md National Institute of Mental Health: 1970; DOI
19. Mizuno Y., Suzuki T., Nakagawa A. et al. Pharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis. Schizophrenia Bull: 2014; 10.1093/schbul/sbu030
20. Cohn L. D., Becker B. J. How meta-analysis increases statistical power. Psychol Meth: 2003; 8 243 253
21. Moher D., Liberati A., Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ: 2009; 339 b2535
22. Overall J. E., Gorham D. R. The Brief Psychiatric Rating Scale. Psychol Rep: 1962; 10 799 812
23. Simpson G. M., Angus J. W. A rating scale for extrapyramidal side effects. Acta psychiatrica Scand Suppl: 1970; 212 11 19
24. DerSimonian R., Laird N. Meta-analysis in clinical trials. Controlled clinical trials: 1986; 7 177 188
25. Higgins J. P., Thompson S. G., Deeks J. J. et al. Measuring inconsistency in meta-analyses. BMJ: 2003; 327 557 560